BIOGEN INC. Cash and Cash Equivalents
BIOGEN INC. (BIIB) had Cash and Cash Equivalents of $2.91 billion as of 2019-12-31, per its 10-K filed 2020-02-06.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2020-02-06
- 2019-12-31: Cash and Cash Equivalents, at Carrying Value $2.91B.
- 2019-09-30: Cash and Cash Equivalents, at Carrying Value $2.34B.
- 2019-06-30: Cash and Cash Equivalents, at Carrying Value $1.72B.
- 2019-03-31: Cash and Cash Equivalents, at Carrying Value $2.24B.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2019-12-31 | $2.91B 10-K · filed 2020-02-06 | |
| 2019-09-30 | $2.34B 10-Q · filed 2019-10-22 | |
| 2019-06-30 | $1.72B 10-Q · filed 2019-07-24 | |
| 2019-03-31 | $2.24B 10-Q · filed 2019-04-24 | |
| 2018-12-31 | $1.22B 10-K · filed 2020-02-06 | |
| 2018-09-30 | $2.39B 10-Q · filed 2019-10-22 | |
| 2018-06-30 | $1.25B 10-Q · filed 2019-07-24 | |
| 2018-03-31 | $4.11B 10-Q · filed 2019-04-24 | |
| 2017-12-31 | $1.57B 10-K · filed 2020-02-06 | |
| 2017-09-30 | $1.55B 10-Q · filed 2018-10-23 | |
| 2017-06-30 | $1.17B 10-Q · filed 2018-07-24 | $1.17B 10-Q · filed 2017-07-25 |
| 2017-03-31 | $924.00M 10-Q · filed 2018-04-24 | |
| 2016-12-31 | $2.33B 10-K · filed 2020-02-06 | |
| 2016-09-30 | $2.08B 10-Q · filed 2017-10-24 | |
| 2016-06-30 | $1.36B 10-Q · filed 2017-07-25 | |
| 2016-03-31 | $1.13B 10-Q · filed 2017-04-25 | |
| 2015-12-31 | $1.31B 10-K · filed 2019-02-06 | |
| 2015-09-30 | $4.09B 10-Q · filed 2016-10-26 | $4.09B 10-Q · filed 2015-10-21 |
| 2015-06-30 | $1.28B 10-Q · filed 2016-07-21 | $1.28B 10-Q · filed 2015-07-24 |
| 2015-03-31 | $1.48B 10-Q · filed 2016-04-21 | $1.48B 10-Q · filed 2015-04-24 |
| 2014-12-31 | $1.20B 10-K · filed 2018-02-01 | $1.20B 10-K · filed 2015-02-04 |
| 2014-09-30 | $1.19B 10-Q · filed 2015-10-21 | |
| 2014-06-30 | $863.20M 10-Q · filed 2015-07-24 | |
| 2014-03-31 | $828.60M 10-Q · filed 2015-04-24 | |
| 2013-12-31 | $602.60M 10-K · filed 2017-02-02 | $602.56M 10-K · filed 2014-02-06 |
| 2013-09-30 | $427.81M 10-Q · filed 2014-10-22 | |
| 2013-06-30 | $392.51M 10-Q · filed 2014-07-23 | |
| 2013-03-31 | $663.30M 10-Q · filed 2014-04-23 | |
| 2012-12-31 | $570.70M 10-K · filed 2016-02-03 | $570.72M 10-K · filed 2013-02-05 |
| 2012-09-30 | $451.72M 10-Q · filed 2013-10-28 | |
| 2012-06-30 | $456.81M 10-Q · filed 2013-07-25 | |
| 2012-03-31 | $298.14M 10-Q · filed 2013-04-25 | |
| 2011-12-31 | $514.54M 10-K · filed 2015-02-04 | |
| 2011-09-30 | $575.14M 10-Q · filed 2012-10-25 | |
| 2011-06-30 | $697.53M 10-Q · filed 2012-07-24 | |
| 2011-03-31 | $790.67M 10-Q · filed 2012-05-01 | |
| 2010-12-31 | $759.60M 10-K · filed 2014-02-06 | |
| 2010-09-30 | $626.76M 10-Q · filed 2011-10-28 | |
| 2010-06-30 | $720.96M 10-Q · filed 2011-07-26 | |
| 2010-03-31 | $639.56M 10-Q · filed 2011-04-21 | |
| 2009-12-31 | $581.89M 10-K · filed 2013-02-05 | |
| 2009-09-30 | $585.79M 10-Q · filed 2010-10-26 | |
| 2009-06-30 | $786.80M 10-Q · filed 2010-07-20 | |
| 2009-03-31 | $764.10M 10-Q · filed 2010-04-20 | |
| 2008-12-31 | $622.38M 10-K · filed 2012-02-03 | |
| 2008-09-30 | $1.01B 10-Q · filed 2009-10-21 | |
| 2008-06-30 | $466.49M 10-Q · filed 2009-07-17 | |
| 2007-12-31 | $659.66M 10-K · filed 2011-02-04 | |
| 2006-12-31 | $661.38M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |